Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMFL96Z)

Drug Name
Pegamotecan Drug Info
Synonyms Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
Indication
Disease Entry ICD 11 Status REF
Esophageal cancer 2B70 Phase 2 [1]
Cross-matching ID
PubChem CID
11297617
CAS Number
CAS 581079-18-7
TTD Drug ID
DMFL96Z

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Esophageal cancer
ICD Disease Classification 2B70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
DNA topoisomerase I (TOP1) DTT TOP1 6.65E-01 0.2 0.39
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00080002) Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
2 A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70.